Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2021. You are requested to take the same on record.
27-11-2021
Bigul

Sequent Scientific Ltd - 512529 - Intimation Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Cessation Of Elysian Life Science Private Limited, As A Wholly Owned Subsidiary Of The Company Consequent Of Strike Off Of Name By The Registrar Of Companies

 With reference to the captioned subject, we would like to inform you that upon voluntary application made by Elysian Life Science Private Limited ('ELSPL'), a wholly owned subsidiary of the Company, the Registrar of Companies, Bangalore, Karnataka ('ROC') under the provisions of Section 248 of the Companies Act, 2013, has struck off ELSPL from the Register of Companies vide its order dated November 15, 2021. Consequently, ELSPL has ceased to exist as a Company and as such as a subsidiary of the Company. The details for cessation of a subsidiary as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in Annexure A to this letter. We request you to take the above on record.
16-11-2021
Bigul

Sequent Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be participating in the following investor conferences (through video) where it will interact with Institutional Investors. Periscope Conference hosted by Batlivala & Karani Securities India Pvt. Ltd scheduled on November 18, 2021. Jefferies Healthcare Conference scheduled on November 18, 2021 and November 19, 2021 This is for your information and record
16-11-2021
Bigul

Sequent Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on November 03, 2021 in 'Financial Express' and 'Mumbai Lakshadeep' newspaper providing Extracts of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2021. Kindly take the same on record.
03-11-2021
Bigul

Q2FY22 Quarterly Result Announced for Sequent Scientific Ltd.

 Financial Highlights: Revenues at Rs. 3,506 Million PAT after minority interest at Rs. 143 Million PAT margin at 4.1% Commenting on the Company’s performance, Manish Gupta, Managing Director stated “The current quarter though muted compared to corresponding quarter last year, reflects a growth of 10% as compared to the previous quarter. We saw a sharp recovery in our API business, which saw 21% growth vs Q1 FY22 driven by 25%+ growth in API portfolio (ex-Albendazole) while our formulation business continues to deliver consistent growth across geographies. While the cost environment is concerning for the industry, we have initiated concerted efforts to mitigate the impact of the same. We expect these to start reflecting in our margins in the coming quarter with full benefit from Q4 FY22. We are achieving significant progress in expanding our portfolio through value-added arrangements for vaccines in Turkey and India and have recently concluded another long-term agreement with a top-10 animal health company. Despite a challenging first half of the year, we look at the second half of FY22 with increased confidence as we start reaping benefits from our recent initiatives and deliver a near double-digit growth for the business despite a flat API business for the year.” Result PDF
03-11-2021
Bigul

Sequent Scientific Ltd - 512529 - Intimation Under Regulation 31A Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI LODR)

 Further to the application made by the Company on April 09, 2021 for reclassification of few persons /entities as listed in Annexure 1 from Promoter / Promoter Group to Public category, please find attached approval letter dated November 01, 2021 from National Stock Exchange Limited and letter dated November 02, 2021 from BSE Limited approving the request for reclassification. The reclassification request was made by the promoters listed in Annexure 1 consequent to the Carlyle Group acquiring control of the Company in August 2020. Consequent to the reclassification, the overall promoter holding as on date will be 53.02% as against 53.52% prior to this reclassification. We request you to take the above on record.
02-11-2021

Earnings Call for Q2FY22 of Sequent Scientific

 Conference Call with Sequent Scientific Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
02-11-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Outcome Of Board Meeting Held On November 01, 2021, Along With Unaudited Standalone &Consolidated Financial Results And Press Release For The Quarter And Half Year Ended September 30, 2021

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021.
01-11-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 01, 2021, Along With Unaudited Standalone & Consolidated Financial Results And Press Release For The Quarter And Half Year Ended September 30, 2021

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021.
01-11-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note that the Company has, as a part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Tuesday, November 02, 2021 to discuss its Q2FY22 financial results. The Conference call details are enclosed. Post Results Q2FY22 Conference Call Tuesday, November 02, 2021 at 9:00 A.M. +91 22 6280 1263 +91 22 7115 8213 You are requested to take the same on record.
25-10-2021
Next Page
Close

Let's Open Free Demat Account